Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors.

Lechtenberg BC, Mace PD, Sessions EH, Williamson R, Stalder R, Wallez Y, Roth GP, Riedl SJ, Pasquale EB.

ACS Med Chem Lett. 2017 Jun 12;8(7):726-731. doi: 10.1021/acsmedchemlett.7b00127. eCollection 2017 Jul 13.

2.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Roberts PJ, Der CJ.

Oncogene. 2007 May 14;26(22):3291-310. Review.

PMID:
17496923
3.

MEK1/2 inhibitors in the treatment of gynecologic malignancies.

Miller CR, Oliver KE, Farley JH.

Gynecol Oncol. 2014 Apr;133(1):128-37. doi: 10.1016/j.ygyno.2014.01.008. Epub 2014 Jan 14. Review.

PMID:
24434059
4.

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.

Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, Cheng J, Hunsaker T, Shao L, Wang SJ, Wagle MC, Lin E, Haverty PM, Shahidi-Latham S, Ngu H, Solon M, Eastham-Anderson J, Koeppen H, Huang SA, Schwarz J, Belvin M, Kirouac D, Junttila MR.

PLoS One. 2017 Oct 5;12(10):e0185862. doi: 10.1371/journal.pone.0185862. eCollection 2017. Erratum in: PLoS One. 2018 Jan 25;13(1):e0192059.

5.

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy.

Liu F, Yang X, Geng M, Huang M.

Acta Pharm Sin B. 2018 Jul;8(4):552-562. doi: 10.1016/j.apsb.2018.01.008. Epub 2018 Feb 16. Review.

6.

ERK inhibition overcomes acquired resistance to MEK inhibitors.

Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR.

Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8.

7.

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF, Rizos H.

Mol Oncol. 2014 May;8(3):544-54. doi: 10.1016/j.molonc.2014.01.003. Epub 2014 Jan 15.

8.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA.

Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. Epub 2006 Oct 7. Review.

9.

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.

Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C.

Mol Cancer. 2017 Jun 8;16(1):102. doi: 10.1186/s12943-017-0667-y.

10.

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.

Wang AX, Qi XY.

IUBMB Life. 2013 Sep;65(9):748-58. doi: 10.1002/iub.1193. Epub 2013 Jul 29. Review.

11.

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA.

Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Review.

PMID:
21494257
12.

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S.

Nature. 2014 Sep 4;513(7516):105-9. doi: 10.1038/nature13572. Epub 2014 Jul 27.

PMID:
25079330
13.

Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo.

Kaoud TS, Johnson WH, Ebelt ND, Piserchio A, Zamora-Olivares D, Van Ravenstein SX, Pridgen JR, Edupuganti R, Sammons R, Cano M, Warthaka M, Harger M, Tavares CDJ, Park J, Radwan MF, Ren P, Anslyn EV, Tsai KY, Ghose R, Dalby KN.

Nat Commun. 2019 Nov 19;10(1):5232. doi: 10.1038/s41467-019-12996-8.

14.

The ERK cascade inhibitors: Towards overcoming resistance.

Maik-Rachline G, Seger R.

Drug Resist Updat. 2016 Mar;25:1-12. doi: 10.1016/j.drup.2015.12.001. Epub 2016 Jan 2. Review.

PMID:
27155372
15.

Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.

Adler V, Qu Y, Smith SJ, Izotova L, Pestka S, Kung HF, Lin M, Friedman FK, Chie L, Chung D, Boutjdir M, Pincus MR.

Biochemistry. 2005 Aug 16;44(32):10784-95.

PMID:
16086581
16.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
17.
18.

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM.

Clin Cancer Res. 2014 May 15;20(10):2516-22. doi: 10.1158/1078-0432.CCR-13-1081. Epub 2014 Mar 24.

19.

A historical overview of protein kinases and their targeted small molecule inhibitors.

Roskoski R Jr.

Pharmacol Res. 2015 Oct;100:1-23. doi: 10.1016/j.phrs.2015.07.010. Epub 2015 Jul 21. Review.

PMID:
26207888
20.

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.

Goetz EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA.

Cancer Res. 2014 Dec 1;74(23):7079-89. doi: 10.1158/0008-5472.CAN-14-2073. Epub 2014 Oct 15.

Supplemental Content

Support Center